Notice of 2026 Annual General Meeting Sydney, Australia, 7 October 2026: Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) (the Company), attaches the following documents in relation to its 2026 Annual General Meeting: 1. Notice of 2026 Annual General Meeting (Notice); 2. Proxy Form; and 3. Access...
Recce Pharmaceuticals: Notice of Annual General Meeting/Proxy Form
Filed with ASX · · 43 pages · English
Summary by 6ix AI
Recce Pharmaceuticals Ltd. has issued a notice for its upcoming Annual General Meeting, detailing important information for shareholders regarding the event. The meeting is scheduled to take place at a specific venue and will also be accessible virtually, allowing shareholders to vote and ask questions. The agenda includes the adoption of the Remuneration Report, election and re-election of directors, and various resolutions related to the company's operations. Shareholders are encouraged to submit questions in advance and to participate in the voting process either in person or online.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Recce Pharmaceuticals Ltd. on 6ix
Story so far
Earlier from Recce Pharmaceuticals
- Notification of cessation of securities - RCE
- Resolutions under section 249N of the Corporations Act
- 2026 Annual General Meeting
- Results of General Meeting
- General Meeting Presentation
Later from Recce Pharmaceuticals
- Amendments to Debt Facility with Avenue Capital Group
- Notification regarding unquoted securities - RCE
- Independent Review of Indonesian Phase 3 R327G Trial Data
- License and Commercialisation Agreement in AUS/NZ for R327G
- Quarterly Activities/Appendix 4C Cash Flow Report
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals